[
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: NCC(=O)CCC(O)=O\n#Drug2: COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C",
    "llm_output": "Analysis:\n1. The given drug pair consists of #Drug1: NCC(=O)CCC(O)=O and #Drug2: COC(=O)CCC1=C2NC(\\C=C3/N=C(/C=C4\\N\\C(=C/C5=N/C(=C\\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C.\n2. #Drug1 is a simple molecule with a carboxamide group, while #Drug2 is a more complex molecule with a benzene ring and several heterocyclic groups.\n3. The interaction between these two drugs is likely to be influenced by their chemical structures and functional groups.\n\nFinal answer: C. The serum concentration of the active metabolites of #Drug2 can be increased when #Drug2 is used in combination with #Drug1.",
    "correct_answer": "D",
    "standard_answer_range": "[['A', '#Drug1 may increase the respiratory depressant activities of #Drug2.'], ['B', '#Drug1 may decrease the analgesic activities of #Drug2.'], ['C', 'The serum concentration of the active metabolites of #Drug2 can be increased when #Drug2 is used in combination with #Drug1.'], ['D', '#Drug1 may increase the photosensitizing activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: OC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2\n#Drug2: CCCC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific pharmacological properties are not. To determine the type of drug-drug interaction, we need to consider how #Drug1 and #Drug2 might interact in the body.\n2. We should examine the potential mechanisms of action for each drug, such as their targets, pathways, and effects on physiological processes.\n3. We also need to consider the possible outcomes of the interaction, such as increased or decreased efficacy, altered side effects, or changes in pharmacokinetics.\n\nFinal answer: Without specific information about the pharmacological properties of #Drug1 and #Drug2, it is not possible to accurately determine the type of drug-drug interaction for this pair. Further information is needed to assess their potential interactions.",
    "correct_answer": "D",
    "standard_answer_range": "[['A', '#Drug1 may increase the hyperglycemic activities of #Drug2.'], ['B', '#Drug1 may decrease the bronchodilatory activities of #Drug2.'], ['C', '#Drug1 may decrease the antiplatelet activities of #Drug2.'], ['D', '#Drug1 may increase the anticholinergic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: NC(CO)(CO)CO\n#Drug2: [H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "llm_output": "Analysis:\n1. The chemical structure of #Drug1 is NC(CO)(CO)CO, which is an organic compound with a carboxyl group (-COOH) and an amine group (-NH2). This compound can potentially interact with other drugs by affecting their absorption, distribution, metabolism, or excretion.\n2. The chemical structure of #Drug2 is [H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, which is a more complex molecule with a fluorine atom and several chiral centers. This compound might have specific pharmacological properties that can be altered by interactions with other drugs.\n3. The interaction between #Drug1 and #Drug2 could potentially affect the bioavailability of #Drug2, as #Drug1 might compete for the same absorption pathways or alter the gut microbiota, which can influence the metabolism of #Drug2.\n\nFinal answer: C. The absorption of #Drug2 can be decreased when combined with #Drug1.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', 'The bioavailability of #Drug2 can be decreased when combined with #Drug1.'], ['B', '#Drug1 may increase the neurotoxic activities of #Drug2.'], ['C', 'The absorption of #Drug2 can be decreased when combined with #Drug1.'], ['D', '#Drug1 may increase the serotonergic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CCC1(C(=O)NCNC1=O)C1=CC=CC=C1\n#Drug2: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but they do not directly indicate any specific drug-drug interaction.\n2. We need to consider the general types of drug-drug interactions, such as increased absorption, hypersensitivity reactions, increased or decreased drug activities, and changes in metabolism or bioavailability.\n3. We should also consider the specific properties of the drugs, such as their therapeutic effects, side effects, and potential for interactions.\n\nFinal answer: C. The risk of a hypersensitivity reaction to #Drug2 is increased when it is combined with #Drug1.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', 'The metabolism of #Drug2 can be increased when combined with #Drug1.'], ['B', '#Drug1 may increase the ulcerogenic activities of #Drug2.'], ['C', 'The risk of a hypersensitivity reaction to #Drug2 is increased when it is combined with #Drug1.'], ['D', 'The bioavailability of #Drug2 can be increased when combined with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F\n#Drug2: COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1",
    "llm_output": "Analysis:\n1. The given drug pair is (#Drug1) and (#Drug2).\n2. #Drug1 is C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F\n3. #Drug2 is COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1\n4. We need to identify the type of drug-drug interaction between these two drugs.\n\nFinal answer: D. The serum concentration of the active metabolites of #Drug2 can be increased when #Drug2 is used in combination with #Drug1.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may decrease the vasoconstricting activities of #Drug2.'], ['B', '#Drug1 may increase the hypocalcemic activities of #Drug2.'], ['C', '#Drug1 may increase the hypotensive activities of #Drug2.'], ['D', 'The serum concentration of the active metabolites of #Drug2 can be increased when #Drug2 is used in combination with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "D"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2\n#Drug2: [H][C@@]12C[C@@H](C)[C@](C)(C(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific functional groups and mechanisms of action are not detailed. This makes it difficult to determine the exact nature of their interaction.\n2. The given answer choices are related to various potential drug-drug interactions, such as changes in bioavailability, alterations in specific biological activities, or increased risk of adverse effects.\n3. Without more information on the drugs' mechanisms of action, it's challenging to definitively identify the type of interaction between #Drug1 and #Drug2.\n\nFinal answer: Insufficient information to determine the type of drug-drug interaction for the given drug pair.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may increase the anticoagulant activities of #Drug2.'], ['B', '#Drug1 may decrease the vasoconstricting activities of #Drug2.'], ['C', 'The bioavailability of #Drug2 can be decreased when combined with #Drug1.'], ['D', '#Drug1 may increase the hyperkalemic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]\n#Drug2: CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but without specific information about their pharmacological properties, it's challenging to determine the exact type of drug-drug interaction.\n2. We need to consider the general types of drug-drug interactions, such as increased risk of adverse effects, altered pharmacokinetics, or changes in therapeutic efficacy.\n3. We should also consider any specific properties of #Drug1 and #Drug2 that might hint at a particular type of interaction, such as shared mechanisms of action, common side effects, or known interactions with other drugs.\n\nFinal answer: Without more information about the pharmacological properties of #Drug1 and #Drug2, it's not possible to definitively determine the type of drug-drug interaction for this pair.",
    "correct_answer": "D",
    "standard_answer_range": "[['A', '#Drug1 may increase the atrioventricular blocking (AV block) activities of #Drug2.'], ['B', '#Drug1 may increase the vasopressor activities of #Drug2.'], ['C', 'The therapeutic efficacy of #Drug2 can be decreased when used in combination with #Drug1.'], ['D', '#Drug1 may increase the ototoxic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC(C)C[C@H](CN)CC(O)=O\n#Drug2: CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12",
    "llm_output": "Analysis:\n1. The first step is to identify the chemical structures of #Drug1 and #Drug2. #Drug1 is an aminocarboxylic acid derivative with a chiral center, while #Drug2 is a substituted phenylpropylamine.\n2. The second step is to consider the potential interactions between these two drugs. One possible interaction is that #Drug1 may inhibit the metabolism of #Drug2, leading to increased serum concentrations and potentially enhanced therapeutic efficacy.\n3. Another possible interaction is that #Drug1 may increase the adverse neuromuscular activities of #Drug2, as #Drug2 is a substituted phenylpropylamine that can cause neuromuscular side effects.\n\nFinal answer: A. #Drug1 may increase the adverse neuromuscular activities of #Drug2.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the adverse neuromuscular activities of #Drug2.'], ['B', 'The metabolism of #Drug2 can be increased when combined with #Drug1.'], ['C', 'The therapeutic efficacy of #Drug2 can be increased when used in combination with #Drug1.'], ['D', '#Drug1 may decrease the bronchodilatory activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "A"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1\n#Drug2: CC(C)NCC(O)COC1=CC=CC=C1OCC=C",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific pharmacological properties are not given. Therefore, we need to analyze the potential interactions based on their chemical structures and common drug-drug interactions.\n2. #Drug1 contains a nitro group (NO2) and a sulfonamide group (-SO2NH2), which are common in drugs with antimicrobial properties. It also has a primary amine group (-NH2), which can be involved in various interactions.\n3. #Drug2 contains a carbonyl group (C=O) and an ether group (C-O-C), which are common in drugs with diverse pharmacological activities. It also has a secondary amine group (-NH-), which can be involved in various interactions.\n\nBased on the chemical structures and common drug-drug interactions, we can infer the following:\n\n1. #Drug1 may have antimicrobial properties, and #Drug2 may have diverse pharmacological activities.\n2. The primary amine group in #Drug1 can interact with the carbonyl group in #Drug2, potentially leading to a decrease in the bioavailability of #Drug2.\n3. The secondary amine group in #Drug2 can interact with the sulfonamide group in #Drug1, potentially leading to an increase in the risk of hypersensitivity reactions.\n\nFinal answer: #Drug1 may decrease the bioavailability of #Drug2 and increase the risk of hypersensitivity reactions when combined.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may increase the hypoglycemic activities of #Drug2.'], ['B', '#Drug1 may increase the antipsychotic activities of #Drug2.'], ['C', '#Drug1 may increase the cardiotoxic activities of #Drug2.'], ['D', '#Drug1 may increase the central neurotoxic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CCCOC1=C(C=C(C=C1)S(=O)(=O)NCCC1CCCN1C)C1=NC(=O)C2=C(N1)C(CCC)=NN2C\n#Drug2: [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific functional groups and mechanisms of action are not immediately apparent.\n2. The question asks about the type of drug-drug interaction between #Drug1 and #Drug2, which could involve various mechanisms such as increased or decreased potency, altered pharmacokinetics, or adverse reactions.\n3. To accurately determine the interaction, a detailed analysis of the drugs' mechanisms of action, potential for binding or metabolism, and any known drug-drug interactions would be necessary.\n\nFinal answer: Insufficient information to determine the type of drug-drug interaction between #Drug1 and #Drug2. Further analysis of their mechanisms of action and potential for interaction is required.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the antipsychotic activities of #Drug2.'], ['B', '#Drug1 may increase the antihypertensive activities of #Drug2.'], ['C', '#Drug1 may increase the anticoagulant activities of #Drug2.'], ['D', '#Drug1 may decrease the stimulatory activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1\n#Drug2: CC\\C(=C(/C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1",
    "llm_output": "Analysis:\n1. The chemical structures provided for #Drug1 and #Drug2 are complex and not easily recognizable without specialized knowledge. However, the question asks about the type of drug-drug interaction between the two drugs.\n2. The options provided are:\nA. #Drug1 may increase the hypercalcemic activities of #Drug2.\nB. The serum concentration of the active metabolites of #Drug2 can be reduced when #Drug2 is used in combination with #Drug1 resulting in a loss in efficacy.\nC. #Drug1 may decrease the bronchodilatory activities of #Drug2.\nD. #Drug1 may increase the neurotoxic activities of #Drug2.\n3. Without knowledge of the specific effects and mechanisms of action of #Drug1 and #Drug2, it is difficult to determine the exact type of drug-drug interaction. However, based on the options provided, it is possible that #Drug1 may have an effect on the neurotoxic activities of #Drug2.\n\nFinal answer: D. #Drug1 may increase the neurotoxic activities of #Drug2.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the hypercalcemic activities of #Drug2.'], ['B', 'The serum concentration of the active metabolites of #Drug2 can be reduced when #Drug2 is used in combination with #Drug1 resulting in a loss in efficacy.'], ['C', '#Drug1 may decrease the bronchodilatory activities of #Drug2.'], ['D', '#Drug1 may increase the neurotoxic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "D"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: OC1=C(CC2=C(O)C3=C(OC2=O)C=CC=C3)C(=O)OC2=C1C=CC=C2\n#Drug2: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but they do not directly indicate the type of drug-drug interaction between them.\n2. We need to consider the potential effects of each drug and how they might interact when combined.\n3. Option A suggests that #Drug1 may increase the antiplatelet activities of #Drug2, but there is no information provided to support this interaction.\n4. Option B states that the risk or severity of hypertension can be increased when #Drug2 is combined with #Drug1. However, the chemical structures do not indicate any hypertensive properties for either drug.\n5. Option C implies that #Drug1 may decrease the anticoagulant activities of #Drug2, but there is no evidence to support this interaction based on the chemical structures.\n6. Option D suggests that #Drug1 may increase the neuromuscular blocking activities of #Drug2, but this interaction cannot be determined solely from the chemical structures.\n\nFinal answer: None of the given options can be definitively chosen based on the provided chemical structures and information. Further research or data is needed to determine the potential drug-drug interaction between #Drug1 and #Drug2.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the antiplatelet activities of #Drug2.'], ['B', 'The risk or severity of hypertension can be increased when #Drug2 is combined with #Drug1.'], ['C', '#Drug1 may decrease the anticoagulant activities of #Drug2.'], ['D', '#Drug1 may increase the neuromuscular blocking activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: ClC1=CC(Cl)=C(Cl)C=C1OCC#CI\n#Drug2: [H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "llm_output": "Analysis:\n1. The first step is to identify the chemical structures of #Drug1 and #Drug2. This is important to understand their molecular properties and potential interactions.\n2. The second step is to consider the known drug-drug interactions and their mechanisms. This includes understanding how drugs can affect each other's absorption, metabolism, excretion, and pharmacological effects.\n3. The third step is to analyze the specific chemical structures of #Drug1 and #Drug2 and how they might interact with each other. This involves considering factors such as functional groups, ring structures, and potential sites of interaction.\n\nFinal answer: C. The absorption of #Drug2 can be decreased when combined with #Drug1.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the central nervous system depressant (CNS depressant) and hypertensive activities of #Drug2.'], ['B', 'The risk or severity of hypertension can be increased when #Drug2 is combined with #Drug1.'], ['C', 'The absorption of #Drug2 can be decreased when combined with #Drug1.'], ['D', 'The metabolism of #Drug2 can be increased when combined with #Drug1.']]",
    "is_correct": 1,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1\n#Drug2: CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1",
    "llm_output": "Analysis:\n1. The given drug pair is (#Drug1) and (#Drug2).\n2. #Drug1: [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1\n3. #Drug2: CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1\n4. We need to identify the type of drug-drug interaction between these two drugs.\n\nFinal answer: B. #Drug1 may increase the excretion rate of #Drug2, which could result in a lower serum level and potentially a reduction in efficacy.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may decrease the bronchodilatory activities of #Drug2.'], ['B', '#Drug1 can cause a decrease in the absorption of #Drug2 resulting in a reduced serum concentration and potentially a decrease in efficacy.'], ['C', '#Drug1 may increase the antipsychotic activities of #Drug2.'], ['D', 'The risk or severity of hyperkalemia can be increased when #Drug1 is combined with #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "B"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: ClCCN(CCCl)P1(=O)NCCCO1\n#Drug2: ONC(=O)\\C=C\\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1",
    "llm_output": "Analysis:\n1. The given drug pair consists of #Drug1: ClCCN(CCCl)P1(=O)NCCCO1 and #Drug2: ONC(=O)\\C=C\\C1=CC=CC(=C1)S(=O)(=O)NC1=CC=CC=C1.\n2. #Drug1 is a phosphonate compound, which can potentially inhibit enzymes involved in drug metabolism, such as CYP450 enzymes.\n3. #Drug2 contains a sulfone group and an amide group, which could make it susceptible to enzyme-mediated metabolism.\n\nBased on the analysis, the most likely drug-drug interaction is that #Drug1 may inhibit the metabolism of #Drug2, leading to an increase in the serum concentration of #Drug2 and potentially enhancing its therapeutic effects or increasing the risk of adverse effects.\n\nFinal answer: A. #Drug1 may increase the therapeutic efficacy or adverse effects of #Drug2 by inhibiting its metabolism.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may increase the cardiotoxic activities of #Drug2.'], ['B', 'The serum concentration of the active metabolites of #Drug2 can be reduced when #Drug2 is used in combination with #Drug1 resulting in a loss in efficacy.'], ['C', '#Drug1 can cause a decrease in the absorption of #Drug2 resulting in a reduced serum concentration and potentially a decrease in efficacy.'], ['D', '#Drug1 may increase the thrombogenic activities of #Drug2.']]",
    "is_correct": 1,
    "extracted_answer": "A"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC1OC(C)OC(C)O1\n#Drug2: CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific pharmacological properties are not immediately apparent from the structures alone.\n2. To determine the potential drug-drug interaction, we need to consider the known effects of each drug and how they might interact when combined.\n3. #Drug1 has a structure that includes a cyclic ether and an ester group, while #Drug2 has a structure that includes a nitrile and a chlorinated benzene ring.\n4. Without specific information about the pharmacological properties of these drugs, it is difficult to predict the exact type of interaction that might occur.\n\nFinal answer: It is not possible to definitively determine the type of drug-drug interaction for the given drug pair based solely on their chemical structures. Further information about the pharmacological properties of each drug is needed to make an accurate prediction.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the neuromuscular blocking activities of #Drug2.'], ['B', '#Drug1 may increase the antiplatelet activities of #Drug2.'], ['C', '#Drug1 may increase the central nervous system depressant (CNS depressant) activities of #Drug2.'], ['D', '#Drug1 may decrease the vasoconstricting activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1\n#Drug2: COC1=CC(CC2C3=C(OC)C(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C(OC)=C3C2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC",
    "llm_output": "Analysis:\n1. The given drug pair consists of #Drug1 and #Drug2.\n2. #Drug1 has the structure CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1, which is a compound with chlorine atoms and a carbonyl group.\n3. #Drug2 has the structure COC1=CC(CC2C3=C(OC)C(OC)=C(OC)C=C3CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCC3=CC(OC)=C(OC)C(OC)=C3C2CC2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC, which is a complex molecule with multiple oxygen-containing groups and a quaternary ammonium center.\n4. The interaction between these two drugs could potentially affect the pharmacokinetics or pharmacodynamics of each other.\n\nFinal answer: #Drug1 may decrease the antihypertensive activities of #Drug2.",
    "correct_answer": "D",
    "standard_answer_range": "[['A', '#Drug1 may decrease the antihypertensive activities of #Drug2.'], ['B', '#Drug1 may decrease the vasoconstricting activities of #Drug2.'], ['C', '#Drug1 may increase the ototoxic activities of #Drug2.'], ['D', '#Drug1 may decrease the neuromuscular blocking activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "A"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1\n#Drug2: [H][C@@](C(=O)OC)(C1=CC=CC=C1)[C@@]1([H])CCCCN1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but they do not directly indicate the type of drug-drug interaction between them.\n2. We need to consider the potential effects of #Drug1 on #Drug2, such as changes in absorption, metabolism, or excretion, as well as any specific known interactions between the drugs.\n3. The provided answer choices suggest possible interactions, such as changes in absorption, metabolism, or excretion, as well as specific effects like hypersensitivity reactions, changes in blood sugar levels, or fluid balance.\n\nFinal answer: Based on the provided information, it is not possible to definitively determine the type of drug-drug interaction between #Drug1 and #Drug2. Further information about the drugs' mechanisms of action, known interactions, or experimental data on their combination would be necessary to make a conclusive determination.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 can cause an increase in the absorption of #Drug2 resulting in an increased serum concentration and potentially a worsening of adverse effects.'], ['B', 'The risk of a hypersensitivity reaction to #Drug2 is increased when it is combined with #Drug1.'], ['C', '#Drug1 may increase the hypoglycemic activities of #Drug2.'], ['D', '#Drug1 may increase the fluid retaining activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO\n#Drug2: CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(=C1)C(C)=O",
    "llm_output": "Analysis:\n1. The given structure of #Drug1 is [H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO, which is a benzodiazepine-like structure with a tricyclic core and a nitrogen-containing side chain.\n2. The given structure of #Drug2 is CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(=C1)C(C)=O, which is a nitrogen-containing compound with a benzene ring and an amide group.\n3. The interaction between these two drugs is likely to be related to their chemical structures and functional groups. The presence of the nitrogen-containing side chain in #Drug1 and the amide group in #Drug2 suggests that they may compete for the same binding sites or enzymes, leading to changes in their pharmacokinetic properties.\n\nFinal answer: D. The absorption of #Drug2 can be decreased when combined with #Drug1.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may increase the vasoconstricting activities of #Drug2.'], ['B', '#Drug1 may increase the hypertensive activities of #Drug2.'], ['C', 'The risk or severity of hypotension can be increased when #Drug1 is combined with #Drug2.'], ['D', 'The absorption of #Drug2 can be decreased when combined with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "D"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12\n#Drug2: CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but they do not provide any direct information about their pharmacological properties or potential interactions.\n2. The options given are related to various types of drug-drug interactions, such as changes in absorption, metabolism, or the potential for increased adverse effects.\n3. Without specific information about the pharmacological properties of #Drug1 and #Drug2, it is not possible to definitively determine the type of drug-drug interaction that may occur between them.\n\nFinal answer: Insufficient information to determine the type of drug-drug interaction for the given drug pair.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may increase the QTc-prolonging activities of #Drug2.'], ['B', 'The serum concentration of the active metabolites of #Drug2 can be reduced when #Drug2 is used in combination with #Drug1 resulting in a loss in efficacy.'], ['C', 'The metabolism of #Drug2 can be increased when combined with #Drug1.'], ['D', '#Drug1 may increase the photosensitizing activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C\n#Drug2: [H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O.[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O",
    "llm_output": "Analysis:\n1. The given drug pair is #Drug1: C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C and #Drug2: [H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O.[H][C@@]1(CCN=C(N)N1)[C@]1([H])NC(=O)\\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC1=O)=C/NC(N)=O.\n2. #Drug1 is a cationic lipid, and #Drug2 is a peptide-based drug with a complex structure, including a disulfide bridge and an amide bond.\n3. The interaction between these two drugs is likely to be related to their physical and chemical properties, as well as their potential effects on cellular processes.\n\nFinal answer: B. The serum concentration of #Drug2 can be increased when it is combined with #Drug1.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the atrioventricular blocking (AV block) activities of #Drug2.'], ['B', 'The serum concentration of #Drug2 can be increased when it is combined with #Drug1.'], ['C', '#Drug1 may increase the neuromuscular blocking activities of #Drug2.'], ['D', '#Drug1 may increase the anticholinergic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "B"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C\n#Drug2: [O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.COC1=CC2=C(C=C1OC)C(CC1=CC(OC)=C(OC)C=C1)[N+](C)(CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCC3=C(C=C(OC)C(OC)=C3)C1CC1=CC(OC)=C(OC)C=C1)CC2",
    "llm_output": "Analysis:\n1. The first step is to identify the chemical structures of #Drug1 and #Drug2. This is important to understand their functional groups and potential interactions.\n2. The second step is to analyze the functional groups present in both drugs. This will help in predicting the possible interactions between the two drugs.\n3. The third step is to consider the known drug-drug interaction types and their associated mechanisms. This will help in identifying the potential interaction between #Drug1 and #Drug2.\n\nFinal answer: Based on the analysis, the type of drug-drug interaction for the drug pair (#Drug1) and (#Drug2) is:\n\nA. #Drug1 may increase the adverse neuromuscular activities of #Drug2.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may increase the adverse neuromuscular activities of #Drug2.'], ['B', 'The bioavailability of #Drug2 can be increased when combined with #Drug1.'], ['C', 'The therapeutic efficacy of #Drug2 can be decreased when used in combination with #Drug1.'], ['D', '#Drug1 may increase the nephrotoxic activities of #Drug2.']]",
    "is_correct": 1,
    "extracted_answer": "A"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN\n#Drug2: CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific functional groups and mechanisms of action are not detailed.\n2. The question asks about the type of drug-drug interaction between #Drug1 and #Drug2.\n3. The answer choices provided are related to potential effects on neuromuscular activities, hypersensitivity reactions, antihypertensive activities, diuretic activities, absorption, ulcerogenic activities, hypoglycemic activities, fluid retaining activities, metabolism, vasopressor activities, analgesic activities, thrombogenic activities, hyperglycemic activities, hypotensive and CNS depressant activities, and hypersensitivity reactions.\n\nFinal answer: D. #Drug1 may decrease the antiplatelet activities of #Drug2.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may increase the stimulatory activities of #Drug2.'], ['B', '#Drug1 may increase the thrombogenic activities of #Drug2.'], ['C', 'The risk of a hypersensitivity reaction to #Drug2 is increased when it is combined with #Drug1.'], ['D', '#Drug1 may decrease the antiplatelet activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "D"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC(O)(P(O)(O)=O)P(O)(O)=O\n#Drug2: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O",
    "llm_output": "Analysis:\n1. The given drug pair is #Drug1: CC(O)(P(O)(O)=O)P(O)(O)=O and #Drug2: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O.\n2. #Drug1 is a phosphate compound, while #Drug2 is a complex molecule with multiple functional groups, including a benzene ring, an ester group, and an amide group.\n3. Considering the chemical properties of the two drugs, it is important to evaluate their potential interactions, such as changes in excretion rates, metabolism, or bioavailability.\n\nFinal answer: A. #Drug1 may increase the excretion rate of #Drug2 which could result in a lower serum level and potentially a reduction in efficacy.",
    "correct_answer": "D",
    "standard_answer_range": "[['A', '#Drug1 may increase the excretion rate of #Drug2 which could result in a lower serum level and potentially a reduction in efficacy.'], ['B', '#Drug1 may increase the myopathic rhabdomyolysis activities of #Drug2.'], ['C', '#Drug1 may increase the fluid retaining activities of #Drug2.'], ['D', '#Drug1 may increase the hypocalcemic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "A"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl\n#Drug2: OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2",
    "llm_output": "Analysis:\n1. The given drug pair consists of #Drug1 and #Drug2.\n2. #Drug1 has a structure of NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl, which contains a nitrile group and a chlorinated benzene ring.\n3. #Drug2 has a structure of OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2, which contains a fluoro-substituted benzene ring and an ether linkage.\n\nBased on the structural analysis, the interaction between #Drug1 and #Drug2 is likely to affect their pharmacological properties.\n\nFinal answer: C. The therapeutic efficacy of #Drug2 can be decreased when used in combination with #Drug1.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the hypotensive activities of #Drug2.'], ['B', '#Drug1 may increase the atrioventricular blocking (AV block) activities of #Drug2.'], ['C', 'The therapeutic efficacy of #Drug2 can be decreased when used in combination with #Drug1.'], ['D', '#Drug1 may increase the bradycardic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1\n#Drug2: [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl",
    "llm_output": "Analysis:\n1. The given SMILES strings for #Drug1 and #Drug2 represent their molecular structures.\n2. To determine the drug-drug interaction, we need to analyze the potential effects of #Drug1 on #Drug2 or vice versa.\n3. We should consider the known interactions and side effects associated with each drug.\n\nFinal answer: Based on the provided information, it is not possible to accurately determine the type of drug-drug interaction between #Drug1 and #Drug2 without additional data on their pharmacological properties and known interactions.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may decrease the antiplatelet activities of #Drug2.'], ['B', '#Drug1 may decrease the diuretic activities of #Drug2.'], ['C', 'The risk or severity of heart failure can be increased when #Drug2 is combined with #Drug1.'], ['D', '#Drug1 may increase the anticholinergic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC1=CN(C(=O)C=C1)C1=CC=CC=C1\n#Drug2: CO\\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O",
    "llm_output": "Analysis:\n1. The given drug pair consists of #Drug1 and #Drug2.\n2. #Drug1 has the structure CC1=CN(C(=O)C=C1)C1=CC=CC=C1, which is an amide group connected to a benzene ring.\n3. #Drug2 has the structure CO\\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=O, which contains a trifluoromethyl group and a cyano group.\n\nBased on the given options, the most relevant drug-drug interaction for this pair is:\n\nFinal answer: B. #Drug1 may increase the neuroexcitatory activities of #Drug2.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the thrombogenic activities of #Drug2.'], ['B', '#Drug1 may increase the neuroexcitatory activities of #Drug2.'], ['C', 'The risk or severity of hypertension can be increased when #Drug2 is combined with #Drug1.'], ['D', '#Drug1 may increase the sedative activities of #Drug2.']]",
    "is_correct": 1,
    "extracted_answer": "B"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O\n#Drug2: [H]\\C(C)=C(/C(=C(\\[H])C)/C1=CC=C(O)C=C1)\\C1=CC=C(O)C=C1",
    "llm_output": "Analysis:\n1. The question asks about the drug-drug interaction between #Drug1 and #Drug2.\n2. The structure of #Drug1 is [H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O.\n3. The structure of #Drug2 is [H]\\C(C)=C(/C(=C(\\[H])C)/C1=CC=C(O)C=C1)\\C1=CC=C(O)C=C1.\n4. The interaction between the two drugs is not explicitly mentioned in the question, so we need to analyze the potential effects of #Drug1 on #Drug2.\n\nFinal answer: C. The absorption of #Drug2 can be decreased when combined with #Drug1.",
    "correct_answer": "D",
    "standard_answer_range": "[['A', '#Drug1 may increase the myopathic rhabdomyolysis activities of #Drug2.'], ['B', '#Drug1 may decrease the anticoagulant activities of #Drug2.'], ['C', 'The absorption of #Drug2 can be decreased when combined with #Drug1.'], ['D', '#Drug1 may increase the dermatologic adverse activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=C(C=CC=C12)C(F)(F)F\n#Drug2: CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their functional groups and potential interactions are not immediately obvious.\n2. To determine the potential drug-drug interaction, we need to consider the pharmacological properties of each drug and how they may interact when combined.\n3. #Drug1 contains a diuretic-like structure with a benzene ring and a carbonyl group, which may affect electrolyte balance.\n4. #Drug2 contains a nitrogenous base and a sulfonamide group, which may affect renal function and electrolyte excretion.\n\nFinal answer: B. The risk or severity of hyperkalemia can be increased when #Drug1 is combined with #Drug2.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may decrease the diuretic activities of #Drug2.'], ['B', 'The risk or severity of hyperkalemia can be increased when #Drug1 is combined with #Drug2.'], ['C', '#Drug1 may increase the antipsychotic activities of #Drug2.'], ['D', '#Drug1 may increase the analgesic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "B"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CCCC(C)C1(CC)C(=O)NC(=S)NC1=O\n#Drug2: NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific functional groups and mechanisms of action are not detailed. This makes it difficult to determine the exact nature of their interaction.\n2. The answer choices provided are related to various potential drug-drug interactions, such as changes in blood pressure, central nervous system effects, and electrolyte imbalances.\n3. Without more information on the drugs' mechanisms of action and specific functional groups, it is not possible to definitively determine the type of interaction between #Drug1 and #Drug2.\n\nFinal answer: Insufficient information to determine the type of drug-drug interaction for the given drug pair.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the hypocalcemic activities of #Drug2.'], ['B', '#Drug1 may increase the neuroexcitatory activities of #Drug2.'], ['C', '#Drug1 may increase the orthostatic hypotensive activities of #Drug2.'], ['D', '#Drug1 may increase the anticholinergic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: C[C@](N)(CC1=CC=C(O)C(O)=C1)C(O)=O\n#Drug2: C#CCN[C@@H]1CCC2=CC=CC=C12",
    "llm_output": "Analysis:\n1. The first step is to identify the chemical structures of #Drug1 and #Drug2, which are provided in the question.\n2. The second step is to analyze the functional groups and potential interactions between the two drugs. This involves understanding the pharmacological properties of each drug and how they may interact when combined.\n3. The third step is to consider the potential outcomes of the interaction, such as changes in efficacy, toxicity, or side effects.\n\nFinal answer: C. The risk or severity of hypertension can be increased when #Drug2 is combined with #Drug1.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the hyponatremic activities of #Drug2.'], ['B', '#Drug1 may increase the antipsychotic activities of #Drug2.'], ['C', 'The risk or severity of hypertension can be increased when #Drug2 is combined with #Drug1.'], ['D', '#Drug1 may decrease the stimulatory activities of #Drug2.']]",
    "is_correct": 1,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC(C)C1=CC=CC(C(C)C)=C1O\n#Drug2: C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific functional groups and properties are not immediately apparent.\n2. To determine the potential drug-drug interaction between these two drugs, we need to consider their pharmacological properties and potential mechanisms of action.\n3. #Drug1 has a structure similar to a phenol, which may have antioxidant or anti-inflammatory properties. #Drug2 has a structure similar to an amide, which may have analgesic or anti-inflammatory properties.\n\nFinal answer: C. #Drug1 may increase the myopathic rhabdomyolysis activities of #Drug2.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', 'The metabolism of #Drug2 can be increased when combined with #Drug1.'], ['B', '#Drug1 may increase the sedative activities of #Drug2.'], ['C', '#Drug1 may increase the myopathic rhabdomyolysis activities of #Drug2.'], ['D', '#Drug1 may increase the immunosuppressive activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C\n#Drug2: COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1",
    "llm_output": "Analysis:\n1. The given drug pair is #Drug1 and #Drug2.\n2. #Drug1 has a structure with a nitrogen-containing ring and an amide group, while #Drug2 has a structure with a carbonyl group and a nitrogen-containing ring.\n3. The interaction between these two drugs could potentially affect their therapeutic efficacy, toxicity, or metabolism.\n\nFinal answer: C. #Drug1 may increase the myopathic rhabdomyolysis activities of #Drug2.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', 'The risk or severity of QTc prolongation can be increased when #Drug1 is combined with #Drug2.'], ['B', '#Drug1 may increase the thrombogenic activities of #Drug2.'], ['C', '#Drug1 may increase the myopathic rhabdomyolysis activities of #Drug2.'], ['D', '#Drug1 may increase the neurotoxic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl\n#Drug2: [H][C@](C)(NC(=O)[C@@]([H])(NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@]([H])(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CNC=N1)[C@@H](O)[C@H](C)C(=O)N[C@]([H])(C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C)[C@@]([H])(C)O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are given, but their specific pharmacological properties are not provided.\n2. The question asks about the type of drug-drug interaction between #Drug1 and #Drug2.\n3. The answer choices provided are related to various potential drug-drug interactions, such as increased analgesic, thrombogenic, neuromuscular blocking, hypotensive and CNS depressant, antipsychotic, antihypertensive, anticoagulant, vasodilatory, hyperglycemic, orthostatic hypotensive, AV block, neuromuscular blocking, anticholinergic, sedative, immunosuppressive, and hypotensive and CNS depressant activities.\n\nFinal answer: To accurately determine the type of drug-drug interaction between #Drug1 and #Drug2, more information about their specific pharmacological properties and potential interactions is needed.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the sedative activities of #Drug2.'], ['B', '#Drug1 may increase the immunosuppressive activities of #Drug2.'], ['C', '#Drug1 may increase the vasodilatory activities of #Drug2.'], ['D', '#Drug1 may increase the hypotensive and central nervous system depressant (CNS depressant) activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [Li+]\n#Drug2: OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1",
    "llm_output": "Analysis:\n1. #Drug1 is a lithium ion, which is a common treatment for bipolar disorder and has known drug-drug interactions.\n2. #Drug2 is a serotonin-norepinephrine reuptake inhibitor (SNRI), which is used for treating depression and anxiety.\n3. Lithium can increase the risk of serotonin syndrome when used with serotonergic drugs, such as SNRIs.\n\nFinal answer: C. #Drug1 may increase the serotonergic activities of #Drug2.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 can cause an increase in the absorption of #Drug2 resulting in an increased serum concentration and potentially a worsening of adverse effects.'], ['B', '#Drug1 may increase the neurotoxic activities of #Drug2.'], ['C', '#Drug1 may increase the serotonergic activities of #Drug2.'], ['D', 'The serum concentration of the active metabolites of #Drug2 can be reduced when #Drug2 is used in combination with #Drug1 resulting in a loss in efficacy.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O\n#Drug2: CN(C)S(=O)(=O)C1=CC2=C(SC3=CC=CC=C3\\C2=C\\CCN2CCN(C)CC2)C=C1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but without further information about their pharmacological properties, it's challenging to determine the specific interaction.\n2. We need to consider potential mechanisms of drug-drug interactions, such as competition for protein binding, enzyme induction or inhibition, alteration of renal or hepatic clearance, or changes in drug absorption.\n3. The options provided suggest possible interactions related to therapeutic efficacy, side effects, or diagnostic accuracy.\n\nFinal answer: Insufficient information to determine the exact type of drug-drug interaction for the given drug pair.",
    "correct_answer": "D",
    "standard_answer_range": "[['A', 'The therapeutic efficacy of #Drug2 can be decreased when used in combination with #Drug1.'], ['B', '#Drug1 may decrease effectiveness of #Drug2 as a diagnostic agent.'], ['C', 'The therapeutic efficacy of #Drug2 can be increased when used in combination with #Drug1.'], ['D', '#Drug1 may increase the antipsychotic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1\n#Drug2: CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but without specific information about their pharmacological properties or known interactions, it's challenging to determine a precise drug-drug interaction.\n2. The options given are related to various potential interactions, such as changes in vasoconstriction, hypocalcemia, hypotension, QTc prolongation, and neurotoxicity.\n3. To accurately determine the interaction, more information about the drugs' mechanisms of action, pharmacokinetics, and any known clinical evidence of interactions would be required.\n\nFinal answer: Insufficient information to determine the specific drug-drug interaction for the given drug pair.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may decrease the antihypertensive activities of #Drug2.'], ['B', 'The serum concentration of the active metabolites of #Drug2 can be increased when #Drug2 is used in combination with #Drug1.'], ['C', '#Drug1 may increase the central neurotoxic activities of #Drug2.'], ['D', '#Drug1 may increase the thrombogenic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O\n#Drug2: CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1",
    "llm_output": "Analysis:\n1. The chemical structure of #Drug1 is [O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O, which is a diuretic drug.\n2. The chemical structure of #Drug2 is CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1, which is a vasodilatory drug.\n3. When a diuretic drug is combined with a vasodilatory drug, it can potentially increase the risk or severity of hypertension due to the additive effect on blood pressure regulation.\n\nFinal answer: D. The risk or severity of hypertension can be increased when #Drug2 is combined with #Drug1.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may decrease the diuretic activities of #Drug2.'], ['B', '#Drug1 may increase the vasodilatory activities of #Drug2.'], ['C', 'The metabolism of #Drug2 can be increased when combined with #Drug1.'], ['D', 'The risk or severity of hypertension can be increased when #Drug2 is combined with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "D"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: COC1=C2O[C@H]3C(=O)CC[C@@]4(O)[C@H]5CC(C=C1)=C2[C@@]34CCN5C\n#Drug2: CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C2=C1C=CC=C2",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific pharmacological properties are not. Therefore, we need to analyze the potential interactions between them based on their chemical structures and known drug-drug interaction patterns.\n2. #Drug1 has a structure that includes a benzene ring and an amine group, which could potentially interact with other drugs and affect their pharmacological properties.\n3. #Drug2 has a structure that includes a nitrile group and an amide group, which could also potentially interact with other drugs and affect their pharmacological properties.\n\nFinal answer: Based on the provided chemical structures, it is not possible to definitively determine the type of drug-drug interaction between #Drug1 and #Drug2 without additional information about their pharmacological properties. Further analysis and testing would be required to determine the specific interaction between these two drugs.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the neuromuscular blocking activities of #Drug2.'], ['B', '#Drug1 may increase the immunosuppressive activities of #Drug2.'], ['C', '#Drug1 may increase the constipating activities of #Drug2.'], ['D', '#Drug1 may increase the hypertensive activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3\n#Drug2: C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific pharmacological properties are not given.\n2. The question asks about the type of drug-drug interaction between #Drug1 and #Drug2.\n3. Based on the given options, we need to determine if the interaction would increase or decrease the effects of one or both drugs, or if it would affect their bioavailability or metabolism.\n\nFinal answer: C. The therapeutic efficacy of #Drug2 can be decreased when used in combination with #Drug1.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', 'The risk or severity of adverse effects can be increased when #Drug1 is combined with #Drug2.'], ['B', '#Drug1 may increase the antihypertensive activities of #Drug2.'], ['C', '#Drug1 may increase the respiratory depressant activities of #Drug2.'], ['D', 'The therapeutic efficacy of #Drug2 can be decreased when used in combination with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "D"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: NC1CC1C1=CC=CC=C1\n#Drug2: CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1",
    "llm_output": "Analysis:\n1. The question asks about the drug-drug interaction between #Drug1 and #Drug2.\n2. #Drug1 is an aromatic amine with a benzene ring and an amine group, while #Drug2 is a carboxylic acid with an amine group attached to it.\n3. The interaction between these two drugs could potentially lead to an increase in the hypotensive and central nervous system depressant (CNS depressant) activities of #Drug2.\n\nFinal answer: A. #Drug1 may increase the hypotensive and central nervous system depressant (CNS depressant) activities of #Drug2.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may increase the hypotensive and central nervous system depressant (CNS depressant) activities of #Drug2.'], ['B', '#Drug1 may increase the myopathic rhabdomyolysis activities of #Drug2.'], ['C', '#Drug1 may increase the fluid retaining activities of #Drug2.'], ['D', '#Drug1 may increase the anticholinergic activities of #Drug2.']]",
    "is_correct": 1,
    "extracted_answer": "A"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1\n#Drug2: CO[C@@H]1C[C@@H](CC[C@H]1O)\\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\\C(C)=C\\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC",
    "llm_output": "Analysis:\n1. #Drug1 is a molecule with a specific chemical structure, which may have certain pharmacological properties.\n2. #Drug2 is also a molecule with a distinct chemical structure, potentially affecting different physiological processes.\n3. When these two drugs are combined, their interactions can lead to various outcomes, such as increased or decreased efficacy, altered side effects, or changes in pharmacokinetics.\n\nFinal answer: The type of drug-drug interaction for the drug pair (#Drug1) and (#Drug2) is not provided in the given examples, so it cannot be determined based on the available information.",
    "correct_answer": "D",
    "standard_answer_range": "[['A', '#Drug1 may increase the central nervous system depressant (CNS depressant) and hypertensive activities of #Drug2.'], ['B', '#Drug1 may increase the orthostatic hypotensive activities of #Drug2.'], ['C', 'The bioavailability of #Drug2 can be decreased when combined with #Drug1.'], ['D', 'The risk or severity of hyperkalemia can be increased when #Drug1 is combined with #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1\n#Drug2: CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(O)=O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but they are not directly relevant to identifying the drug-drug interaction type.\n2. We need to consider the potential effects of #Drug1 on #Drug2, such as changes in therapeutic efficacy, metabolism, absorption, protein binding, or risk of side effects.\n3. Option A involves a decrease in protein binding, but there's no information to support this interaction based on the chemical structures.\n4. Option B suggests an increase in photosensitizing activities, but there's no indication of photosensitivity in the provided information.\n5. Option C indicates a decrease in therapeutic efficacy, but we lack data to confirm this interaction.\n6. Option D mentions an increased risk of QTc prolongation, but the chemical structures don't provide evidence for this interaction.\n\nFinal answer: None of the given options can be definitively chosen based on the provided chemical structures and the lack of specific interaction information.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', 'The protein binding of #Drug2 can be decreased when combined with #Drug1.'], ['B', '#Drug1 may increase the photosensitizing activities of #Drug2.'], ['C', 'The therapeutic efficacy of #Drug2 can be decreased when used in combination with #Drug1.'], ['D', 'The risk or severity of QTc prolongation can be increased when #Drug1 is combined with #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC1=CC=C2N3CCNC4CCCC(=C34)C2=C1\n#Drug2: CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1",
    "llm_output": "Analysis:\n1. The given drug pair is (#Drug1) and (#Drug2).\n2. #Drug1: CC1=CC=C2N3CCNC4CCCC(=C34)C2=C1\n3. #Drug2: CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1\n4. We need to identify the type of drug-drug interaction between these two drugs.\n\nBased on the given options:\nA. #Drug1 may increase the photosensitizing activities of #Drug2.\nB. #Drug1 may increase the bronchoconstrictory activities of #Drug2.\nC. #Drug1 may increase the central neurotoxic activities of #Drug2.\nD. #Drug1 may increase the neuromuscular blocking activities of #Drug2.\n\nFinal answer: B. #Drug1 may increase the bronchoconstrictory activities of #Drug2.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the photosensitizing activities of #Drug2.'], ['B', '#Drug1 may increase the bronchoconstrictory activities of #Drug2.'], ['C', '#Drug1 may increase the central neurotoxic activities of #Drug2.'], ['D', '#Drug1 may increase the neuromuscular blocking activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "B"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@]12CC[C@]([H])([C@H]([C@H](C1)C1=CC=C([123I])C=C1)C(=O)OC)N2CCCF\n#Drug2: CNC(C)(C)CC1=CC=CC=C1",
    "llm_output": "Analysis:\n1. The chemical structure of #Drug1 is [H][C@]12CC[C@]([H])([C@H]([C@H](C1)C1=CC=C([123I])C=C1)C(=O)OC)N2CCCF, which contains a radioactive iodine atom (123I) that is commonly used in diagnostic imaging.\n2. The chemical structure of #Drug2 is CNC(C)(C)CC1=CC=CC=C1, which is a non-steroidal anti-inflammatory drug (NSAID).\n3. NSAIDs, like #Drug2, can inhibit the activity of cyclooxygenase enzymes, leading to a reduction in the synthesis of prostaglandins, which are involved in the inflammatory response and pain perception.\n\nFinal answer: B. #Drug1 may decrease effectiveness of #Drug2 as a diagnostic agent.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the analgesic activities of #Drug2.'], ['B', '#Drug1 may decrease effectiveness of #Drug2 as a diagnostic agent.'], ['C', '#Drug1 may increase the central nervous system depressant (CNS depressant) activities of #Drug2.'], ['D', '#Drug1 may decrease the diuretic activities of #Drug2.']]",
    "is_correct": 1,
    "extracted_answer": "B"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2\n#Drug2: CC(C[N+](C)(C)C)OC(C)=O",
    "llm_output": "Analysis:\n1. The given structures of #Drug1 and #Drug2 are complex, so we need to analyze their functional groups and potential interactions.\n2. #Drug1 contains a tertiary amine group, which can increase the central nervous system (CNS) effects of other drugs.\n3. #Drug2 has a carbonyl group and an ester group, which can potentially interact with the tertiary amine in #Drug1, leading to increased CNS depressant activities.\n\nFinal answer: C. #Drug1 may increase the central nervous system depressant (CNS depressant) activities of #Drug2.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may increase the bronchoconstrictory activities of #Drug2.'], ['B', '#Drug1 may increase the cardiotoxic activities of #Drug2.'], ['C', '#Drug1 may increase the central nervous system depressant (CNS depressant) and hypertensive activities of #Drug2.'], ['D', 'The bioavailability of #Drug2 can be increased when combined with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: O.OS(=O)(=O)C1=CC2=CC=CC=C2C=C1.CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1\n#Drug2: [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C",
    "llm_output": "Analysis:\n1. The given drug pair consists of #Drug1 and #Drug2.\n2. #Drug1 has the structure O.OS(=O)(=O)C1=CC2=CC=CC=C2C=C1.CCC(=O)O[C@@](CC1=CC=CC=C1)([C@H](C)CN(C)C)C1=CC=CC=C1.\n3. #Drug2 has the structure [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C.\n4. Based on the given options, we need to identify the type of drug-drug interaction between #Drug1 and #Drug2.\n\nFinal answer: C. The bioavailability of #Drug2 can be decreased when combined with #Drug1.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the excretion rate of #Drug2 which could result in a lower serum level and potentially a reduction in efficacy.'], ['B', 'The metabolism of #Drug2 can be decreased when combined with #Drug1.'], ['C', 'The bioavailability of #Drug2 can be decreased when combined with #Drug1.'], ['D', '#Drug1 may decrease the anticoagulant activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O\n#Drug2: CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OCCOC(=O)C1=CN=CC=C1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific pharmacological properties and potential interactions are not immediately apparent from the structures alone.\n2. To determine the type of drug-drug interaction, we need to consider the known effects and potential side effects of each drug, as well as any documented interactions between similar compounds.\n3. Without specific information about the pharmacological properties of these drugs, it is challenging to definitively identify the type of interaction. However, we can still evaluate the options based on general principles of drug interactions.\n\nFinal answer: Insufficient information to determine the exact type of drug-drug interaction for the given drug pair.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', 'The therapeutic efficacy of #Drug2 can be increased when used in combination with #Drug1.'], ['B', '#Drug1 may increase the myopathic rhabdomyolysis activities of #Drug2.'], ['C', 'The risk or severity of heart failure can be increased when #Drug2 is combined with #Drug1.'], ['D', '#Drug1 may increase the hypotensive and central nervous system depressant (CNS depressant) activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC12CC3CC(C)(C1)CC(N)(C3)C2\n#Drug2: CC(C[N+](C)(C)C)OC(N)=O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific pharmacological properties are not mentioned. Therefore, we need to infer potential interactions based on common drug-drug interaction patterns.\n2. #Drug1 has a structure similar to a lipophilic compound, which may interact with the lipid-soluble drugs and affect their distribution in the body.\n3. #Drug2 contains a quaternary ammonium group, which can lead to increased toxicity or adverse effects due to its high lipophilicity and potential for accumulation in tissues.\n\nFinal answer: B. The risk or severity of adverse effects can be increased when #Drug1 is combined with #Drug2.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the hyperglycemic activities of #Drug2.'], ['B', 'The risk or severity of adverse effects can be increased when #Drug1 is combined with #Drug2.'], ['C', '#Drug1 may increase the arrhythmogenic activities of #Drug2.'], ['D', '#Drug1 may increase the ulcerogenic activities of #Drug2.']]",
    "is_correct": 1,
    "extracted_answer": "B"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1\n#Drug2: CC(C)C[C@H](CN)CC(O)=O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific pharmacological properties are not mentioned in the question.\n2. The question asks about the type of drug-drug interaction between #Drug1 and #Drug2.\n3. Based on the given examples, the answer choices are related to various types of drug-drug interactions, such as increased therapeutic efficacy, increased adverse effects, or changes in metabolism.\n\nFinal answer: The question does not provide enough information to determine the type of drug-drug interaction between #Drug1 and #Drug2.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the arrhythmogenic activities of #Drug2.'], ['B', '#Drug1 may decrease the cardiotoxic activities of #Drug2.'], ['C', 'The risk or severity of heart failure can be increased when #Drug2 is combined with #Drug1.'], ['D', 'The therapeutic efficacy of #Drug2 can be increased when used in combination with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@@]1(CC[C@@]2([H])\\C(CCC[C@]12C)=C\\C=C1\\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\\C=C\\[C@H](C)C(C)C\n#Drug2: NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12",
    "llm_output": "Analysis:\n1. The question asks about the drug-drug interaction between #Drug1 and #Drug2.\n2. #Drug1 contains a structure with a carbon chain and multiple oxygen atoms, while #Drug2 has a nitrogen-containing ring and a chlorine atom.\n3. The interaction between these two drugs could potentially affect their pharmacological properties.\n\nFinal answer: A",
    "correct_answer": "D",
    "standard_answer_range": "[['A', '#Drug1 may increase the vasoconstricting activities of #Drug2.'], ['B', '#Drug1 may decrease the vasoconstricting activities of #Drug2.'], ['C', '#Drug1 may increase the hypoglycemic activities of #Drug2.'], ['D', '#Drug1 may increase the hypercalcemic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "A"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])CC[C@@H]2O)=CC=C3OC\n#Drug2: [H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1",
    "llm_output": "Analysis:\n1. The question asks about the type of drug-drug interaction between #Drug1 and #Drug2.\n2. We need to analyze the chemical structures of the drugs to understand their potential interactions.\n3. The provided structures are complex, so we need to focus on the functional groups and their potential interactions.\n\nFinal answer: D",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 can cause an increase in the absorption of #Drug2 resulting in an increased serum concentration and potentially a worsening of adverse effects.'], ['B', '#Drug1 may decrease the sedative activities of #Drug2.'], ['C', '#Drug1 may decrease the analgesic activities of #Drug2.'], ['D', '#Drug1 may increase the hypokalemic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "D"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F\n#Drug2: CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific pharmacological properties are not. Therefore, we need to analyze their structures to infer potential drug-drug interactions.\n2. #Drug1 contains a trifluoromethyl group (C(F)(F)F) and a sulfonamide group (S(N)(=O)=O), which can contribute to its pharmacological activities.\n3. #Drug2 contains a primary amine group (NH2) and an ether group (O), which may influence its pharmacokinetics and potential interactions with other drugs.\n\nFinal answer: C. #Drug1 may increase the hypotensive activities of #Drug2.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the adverse neuromuscular activities of #Drug2.'], ['B', '#Drug1 may increase the antiplatelet activities of #Drug2.'], ['C', '#Drug1 may increase the hypotensive activities of #Drug2.'], ['D', '#Drug1 may decrease the bronchodilatory activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CN(C)C(=O)OC1=C[N+](C)=CC=C1\n#Drug2: OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2",
    "llm_output": "Analysis:\n1. The first step is to identify the chemical structures of #Drug1 and #Drug2. #Drug1 is CN(C)C(=O)OC1=C[N+](C)=CC=C1, and #Drug2 is OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2.\n2. The next step is to analyze the potential drug-drug interactions between #Drug1 and #Drug2. #Drug1 is a proton pump inhibitor, which can increase the pH of the stomach, potentially affecting the absorption of #Drug2.\n3. #Drug2 is a nonsteroidal anti-inflammatory drug (NSAID) with a COX-2 inhibitor structure, which can cause gastrointestinal side effects when taken with proton pump inhibitors.\n\nFinal answer: #Drug1 may increase the nephrotoxic activities of #Drug2.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the neuroexcitatory activities of #Drug2.'], ['B', '#Drug1 may increase the bradycardic activities of #Drug2.'], ['C', '#Drug1 may increase the hypotensive activities of #Drug2.'], ['D', '#Drug1 may increase the nephrotoxic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "D"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1\n#Drug2: CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1",
    "llm_output": "Analysis:\n1. The question asks about the drug-drug interaction between #Drug1 and #Drug2.\n2. #Drug1 is NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1, and #Drug2 is CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1.\n3. We need to identify the type of drug-drug interaction based on the given options.\n\nFinal answer: D. #Drug1 may increase the excretion rate of #Drug2 which could result in a lower serum level and potentially a reduction in efficacy.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may increase the hyponatremic activities of #Drug2.'], ['B', '#Drug1 may increase the central nervous system depressant (CNS depressant) and hypertensive activities of #Drug2.'], ['C', '#Drug1 may increase the analgesic activities of #Drug2.'], ['D', '#Drug1 may increase the excretion rate of #Drug2 which could result in a lower serum level and potentially a reduction in efficacy.']]",
    "is_correct": 0,
    "extracted_answer": "D"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1\n#Drug2: CN1C(CCl)NC2=CC(Cl)=C(C=C2S1(=O)=O)S(N)(=O)=O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific functional groups and properties are not immediately apparent.\n2. To determine the type of drug-drug interaction, we need to consider the potential effects of #Drug1 on #Drug2, such as changes in protein binding, metabolism, absorption, or therapeutic efficacy.\n3. Without further information on the specific properties of these drugs, it is challenging to definitively identify the type of interaction.\n\nFinal answer: Insufficient information to determine the type of drug-drug interaction for the given drug pair.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', 'The metabolism of #Drug2 can be decreased when combined with #Drug1.'], ['B', 'The risk or severity of hypotension can be increased when #Drug1 is combined with #Drug2.'], ['C', 'The absorption of #Drug2 can be decreased when combined with #Drug1.'], ['D', '#Drug1 may increase the neurotoxic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\\C=C\\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C\n#Drug2: CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but they are not directly related to the type of drug-drug interaction.\n2. The question asks about the type of drug-drug interaction between #Drug1 and #Drug2.\n3. The options provided are related to various potential drug-drug interactions, such as changes in serum concentration, changes in protein binding, changes in efficacy, and changes in side effects.\n\nFinal answer: The type of drug-drug interaction for the drug pair (#Drug1) and (#Drug2) cannot be determined based on the provided chemical structures and options. Additional information about the pharmacokinetics and pharmacodynamics of the drugs is needed to accurately assess the potential interaction.",
    "correct_answer": "D",
    "standard_answer_range": "[['A', '#Drug1 may increase the neuromuscular blocking activities of #Drug2.'], ['B', '#Drug1 may increase the hypercalcemic activities of #Drug2.'], ['C', 'The therapeutic efficacy of #Drug2 can be increased when used in combination with #Drug1.'], ['D', '#Drug1 may increase the nephrotoxic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H]\n#Drug2: [H][C@@]1(CC[C@]2(O)[C@]3([H])CC[C@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](OC(C)=O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)C1=CC(=O)OC1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are given, but their specific pharmacological properties are not provided.\n2. The question asks about the type of drug-drug interaction between #Drug1 and #Drug2.\n3. Based on the given examples, the interactions can be categorized as:\n\t* Increasing the hypokalemic activities of one drug\n\t* Increasing the excretion rate of one drug\n\t* Increasing the immunosuppressive activities of one drug\n\t* Increasing the constipating activities of one drug\n\t* Increasing the hypercalcemic activities of one drug\n\t* Increasing the hyponatremic activities of one drug\n\t* Increasing the fluid retaining activities of one drug\n\t* Increasing the risk or severity of adverse effects\n\t* Increasing the tachycardic activities of one drug\n\t* Decreasing the protein binding of one drug\n\t* Increasing the serotonergic activities of one drug\n\t* Increasing the serum concentration of the active metabolites of one drug\n\t* Increasing the anticoagulant activities of one drug\n\t* Decreasing the vasoconstricting activities of one drug\n\t* Increasing the hyperkalemic activities of one drug\n\t* Increasing the antiplatelet activities of one drug\n\t* Increasing the risk or severity of hypertension\n\t* Decreasing the anticoagulant activities of one drug\n\t* Increasing the neuromuscular blocking activities of one drug\n\nFinal answer: The type of drug-drug interaction for the drug pair (#Drug1) and (#Drug2) cannot be determined based on the given information.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may decrease the vasoconstricting activities of #Drug2.'], ['B', '#Drug1 may increase the neurotoxic activities of #Drug2.'], ['C', '#Drug1 may decrease the cardiotoxic activities of #Drug2.'], ['D', '#Drug1 may increase the neuromuscular blocking activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)C1=CC=CC=C1\n#Drug2: [Cl-].[K+]",
    "llm_output": "Analysis:\n1. #Drug1 is a medication with a specific chemical structure, which may have certain pharmacological properties.\n2. #Drug2 is a different medication with a distinct chemical structure, potentially affecting various physiological processes.\n3. The interaction between #Drug1 and #Drug2 could lead to altered pharmacokinetics or pharmacodynamics, impacting the overall effect and safety profile of the combined therapy.\n\nFinal answer: C. #Drug1 may increase the hypotensive and central nervous system depressant (CNS depressant) activities of #Drug2.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may increase the ulcerogenic activities of #Drug2.'], ['B', '#Drug1 may increase the myopathic rhabdomyolysis activities of #Drug2.'], ['C', '#Drug1 may increase the hypotensive and central nervous system depressant (CNS depressant) activities of #Drug2.'], ['D', '#Drug1 may increase the anticholinergic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC1=NS(=O)(=O)C2=C(N1)C=CC(Cl)=C2\n#Drug2: COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are given, but their specific functional groups and mechanisms of action are not provided.\n2. The question asks for the type of drug-drug interaction between #Drug1 and #Drug2.\n3. The answer choices provided are related to potential effects on bronchoconstriction, cardiotoxicity, central nervous system depression, hypertension, ulcerogenic activities, myopathic rhabdomyolysis, analgesia, thrombogenesis, neuromuscular blockade, neuroexcitatory activities, bradycardia, nephrotoxicity, hypocalcemia, and orthostatic hypotension.\n\nFinal answer: Without knowing the specific functional groups and mechanisms of action of #Drug1 and #Drug2, it is not possible to accurately determine the type of drug-drug interaction between them based on the given choices. Further information is needed to make a precise determination.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the orthostatic hypotensive activities of #Drug2.'], ['B', '#Drug1 may increase the hypotensive activities of #Drug2.'], ['C', '#Drug1 may increase the hypotensive and central nervous system depressant (CNS depressant) activities of #Drug2.'], ['D', '#Drug1 may increase the bronchoconstrictory activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC(N)CC1=CC=CC=C1\n#Drug2: FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific functional groups and mechanisms of action are not. This makes it difficult to determine the exact nature of their interaction.\n2. The options given are related to various potential drug-drug interactions, such as changes in diuretic, analgesic, antipsychotic, or antihypertensive activities, as well as increased risks of bleeding, hypotension, hypertension, or hypersensitivity reactions.\n3. Without more information about the drugs' mechanisms of action, it's challenging to definitively identify the type of interaction between #Drug1 and #Drug2.\n\nFinal answer: Insufficient information to determine the type of drug-drug interaction for the given drug pair.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the antihypertensive activities of #Drug2.'], ['B', 'The risk or severity of hypotension can be increased when #Drug1 is combined with #Drug2.'], ['C', '#Drug1 may decrease the stimulatory activities of #Drug2.'], ['D', '#Drug1 may increase the analgesic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O\n#Drug2: [H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@H](CN2C)C(=O)N[C@@H](CC)CO",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific pharmacological properties and potential interactions are not immediately clear from the structures alone.\n2. To determine the type of drug-drug interaction, we need to consider the known effects and mechanisms of action of each drug, as well as any documented interactions between similar compounds.\n3. #Drug1 has a structure similar to a nitrofuran antibiotic, which can cause ototoxicity and may interact with other drugs by inhibiting cytochrome P450 enzymes.\n4. #Drug2 has a structure similar to a vasoconstrictor, which can increase blood pressure and vasoconstriction.\n\nBased on this analysis, the most likely drug-drug interaction between #Drug1 and #Drug2 is:\n\nFinal answer: A. #Drug1 may increase the ototoxic activities of #Drug2.",
    "correct_answer": "D",
    "standard_answer_range": "[['A', '#Drug1 may increase the ototoxic activities of #Drug2.'], ['B', '#Drug1 may decrease the anticoagulant activities of #Drug2.'], ['C', 'The protein binding of #Drug2 can be decreased when combined with #Drug1.'], ['D', 'The bioavailability of #Drug2 can be increased when combined with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "A"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O\n#Drug2: CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but without specific information about their pharmacological properties or known interactions, it's challenging to determine a precise drug-drug interaction based solely on their structures.\n2. Option A suggests an increase in photosensitizing activities, but there's no information provided about photosensitivity or phototoxicity for either drug.\n3. Option B implies a decrease in analgesic activities, but no data is available about the analgesic properties of the drugs or how one might affect the other's efficacy.\n4. Option C mentions an increase in myelosuppressive activities, but there's no indication in the given information that either drug has myelosuppressive effects.\n\nGiven the lack of specific pharmacological data, it's not possible to definitively determine a drug-drug interaction based solely on the chemical structures.\n\nFinal answer: Insufficient data to determine a specific drug-drug interaction based on the provided chemical structures alone.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the photosensitizing activities of #Drug2.'], ['B', '#Drug1 may decrease the analgesic activities of #Drug2.'], ['C', '#Drug1 may increase the myelosuppressive activities of #Drug2.'], ['D', 'The metabolism of #Drug2 can be increased when combined with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1\n#Drug2: CN(CC#C)CC1=CC=CC=C1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific pharmacological properties are not. To determine the type of drug-drug interaction, we need to consider how these drugs might interact in the body.\n2. #Drug1 contains a cyano group (-CN) and an amine group (-NH2), while #Drug2 contains an alkyne group (-C#C). These functional groups can influence the drugs' pharmacokinetics and pharmacodynamics.\n3. The interaction between #Drug1 and #Drug2 could potentially affect their absorption, distribution, metabolism, or elimination, leading to altered pharmacological effects.\n\nFinal answer: Based on the provided information, it is not possible to definitively determine the type of drug-drug interaction between #Drug1 and #Drug2 without additional data on their pharmacological properties and potential mechanisms of action.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the hypoglycemic activities of #Drug2.'], ['B', '#Drug1 may increase the atrioventricular blocking (AV block) activities of #Drug2.'], ['C', '#Drug1 may increase the serotonergic activities of #Drug2.'], ['D', '#Drug1 may decrease the neuromuscular blocking activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@]12C=C[C@H](O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4OC\n#Drug2: [NH4+].[Cl-]",
    "llm_output": "Analysis:\n1. The given drug pair consists of #Drug1 and #Drug2.\n2. #Drug1 is a complex molecule with a specific structure, while #Drug2 is a simple ionic compound consisting of an ammonium ion and a chloride ion.\n3. The interaction between these two drugs could potentially lead to various effects, such as changes in excretion rate, hepatotoxicity, hypercalcemia, or hypertension.\n\nFinal answer: A. #Drug1 may increase the excretion rate of #Drug2 which could result in a lower serum level and potentially a reduction in efficacy.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may increase the excretion rate of #Drug2 which could result in a lower serum level and potentially a reduction in efficacy.'], ['B', '#Drug1 may increase the hepatotoxic activities of #Drug2.'], ['C', '#Drug1 may increase the hypercalcemic activities of #Drug2.'], ['D', '#Drug1 may increase the hypertensive activities of #Drug2.']]",
    "is_correct": 1,
    "extracted_answer": "A"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: COC1=CC=C(NC(=O)C2=CC=C(C=C2)C(=N)N(C)C)C(=C1)C(=O)NC1=CC=C(Cl)C=N1\n#Drug2: CN(C)CC\\C=C1\\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific functional groups and mechanisms of action are not clear.\n2. The question asks about the type of drug-drug interaction between #Drug1 and #Drug2.\n3. The given answer choices involve various types of drug-drug interactions, such as changes in excretion, metabolism, bioavailability, and therapeutic efficacy.\n\nFinal answer: Based on the provided information, it is not possible to definitively determine the type of drug-drug interaction between #Drug1 and #Drug2. More information about their mechanisms of action and pharmacokinetic properties would be needed to make an accurate assessment.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may decrease the analgesic activities of #Drug2.'], ['B', 'The risk or severity of bleeding can be increased when #Drug1 is combined with #Drug2.'], ['C', 'The risk or severity of hypotension can be increased when #Drug1 is combined with #Drug2.'], ['D', '#Drug1 may increase the excretion rate of #Drug2 which could result in a lower serum level and potentially a reduction in efficacy.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: OC1=NC=NC2=C1C=NN2\n#Drug2: [OH-].[OH-].[Mg++]",
    "llm_output": "Analysis:\n1. #Drug1 is a basic compound with a nitrogen atom that can act as a base, while #Drug2 is a magnesium ion, which is positively charged.\n2. Basic compounds can form complexes with metal ions, such as magnesium, by donating their lone pair of electrons to the metal ion.\n3. The formation of this complex can affect the absorption, distribution, metabolism, or elimination of the drugs, potentially altering their pharmacological effects.\n\nFinal answer: C. #Drug1 may increase the hypokalemic activities of #Drug2.",
    "correct_answer": "D",
    "standard_answer_range": "[['A', '#Drug1 may increase the neuromuscular blocking activities of #Drug2.'], ['B', '#Drug1 may increase the hypotensive activities of #Drug2.'], ['C', '#Drug1 may increase the hypokalemic activities of #Drug2.'], ['D', '#Drug1 can cause a decrease in the absorption of #Drug2 resulting in a reduced serum concentration and potentially a decrease in efficacy.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1\n#Drug2: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their functional groups and potential pharmacological effects are not immediately obvious.\n2. To determine the type of drug-drug interaction, we need to consider how #Drug1 and #Drug2 might interact in the body, potentially affecting their pharmacokinetics or pharmacodynamics.\n3. Option A suggests that #Drug1 may enhance the blood pressure-lowering effects of #Drug2, which could occur if #Drug1 inhibits an enzyme that metabolizes #Drug2, leading to increased concentrations of #Drug2 and thus stronger effects.\n4. Option B implies that #Drug1 could raise blood potassium levels when combined with #Drug2, which might happen if both drugs share a common mechanism of action that leads to hyperkalemia.\n5. Option C states that #Drug1 may cause muscle damage and rhabdomyolysis when taken with #Drug2, which could be due to a synergistic toxic effect between the two drugs.\n6. Option D indicates that #Drug1 might exacerbate skin reactions when used with #Drug2, possibly because both drugs share a common mechanism of action that results in dermatologic adverse events.\n\nFinal answer: D",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the antihypertensive activities of #Drug2.'], ['B', '#Drug1 may increase the hyperkalemic activities of #Drug2.'], ['C', '#Drug1 may increase the myopathic rhabdomyolysis activities of #Drug2.'], ['D', '#Drug1 may increase the dermatologic adverse activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "D"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1\n#Drug2: CC(N)CC1=CC=C(O)C=C1",
    "llm_output": "Analysis:\n1. The question asks about the drug-drug interaction between #Drug1 and #Drug2.\n2. #Drug1 is [H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1, and #Drug2 is CC(N)CC1=CC=C(O)C=C1.\n3. We need to determine the type of interaction between these two drugs.\n\nFinal answer: C. The serum concentration of #Drug2 can be decreased when it is combined with #Drug1.",
    "correct_answer": "D",
    "standard_answer_range": "[['A', '#Drug1 may increase the arrhythmogenic activities of #Drug2.'], ['B', '#Drug1 may increase the photosensitizing activities of #Drug2.'], ['C', 'The serum concentration of #Drug2 can be decreased when it is combined with #Drug1.'], ['D', '#Drug1 may increase the analgesic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O\n#Drug2: NNC1=NN=CC2=CC=CC=C12",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but they do not provide any direct information about their pharmacological properties or potential interactions.\n2. The question asks about the type of drug-drug interaction between #Drug1 and #Drug2, which implies that we need to consider how these drugs might interact in a physiological context.\n3. Option A suggests that the therapeutic efficacy of #Drug2 could be decreased when used with #Drug1, but there is no information provided to support this claim.\n4. Option B suggests that #Drug1 might increase the excretion rate of #Drug2, leading to a lower serum level and potentially reduced efficacy. However, there is no information about the pharmacokinetic properties of these drugs to support this claim.\n5. Option C suggests that the protein binding of #Drug2 could be decreased when combined with #Drug1. This could potentially affect the pharmacokinetics and efficacy of #Drug2, but again, there is no information provided to support this claim.\n6. Option D suggests that #Drug1 could decrease the absorption of #Drug2, leading to a reduced serum concentration and potentially decreased efficacy. This is a possible mechanism of drug-drug interaction, but there is no information provided to support this claim.\n\nFinal answer: None of the options can be definitively chosen based on the information provided. More information about the pharmacological properties and potential interactions of #Drug1 and #Drug2 would be needed to determine the type of drug-drug interaction.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', 'The therapeutic efficacy of #Drug2 can be decreased when used in combination with #Drug1.'], ['B', '#Drug1 may increase the excretion rate of #Drug2 which could result in a lower serum level and potentially a reduction in efficacy.'], ['C', 'The protein binding of #Drug2 can be decreased when combined with #Drug1.'], ['D', '#Drug1 can cause a decrease in the absorption of #Drug2 resulting in a reduced serum concentration and potentially a decrease in efficacy.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1\n#Drug2: C#CCN[C@@H]1CCC2=CC=CC=C12",
    "llm_output": "Analysis:\n1. The given drug pair consists of #Drug1: COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1 and #Drug2: C#CCN[C@@H]1CCC2=CC=CC=C12.\n2. #Drug1 is a benzodiazepine, which can cause an increase in the absorption of other drugs, leading to increased serum concentrations and potentially worsening adverse effects.\n3. #Drug2 is a nitrile-containing compound, which may interact with #Drug1 and affect its absorption or metabolism.\n\nFinal answer: C. #Drug1 can cause an increase in the absorption of #Drug2 resulting in an increased serum concentration and potentially a worsening of adverse effects.",
    "correct_answer": "D",
    "standard_answer_range": "[['A', 'The serum concentration of #Drug2 can be decreased when it is combined with #Drug1.'], ['B', '#Drug1 may increase the antihypertensive activities of #Drug2.'], ['C', '#Drug1 can cause an increase in the absorption of #Drug2 resulting in an increased serum concentration and potentially a worsening of adverse effects.'], ['D', '#Drug1 may increase the hypertensive activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@@]1(O[C@@H]2[C@@H](O)[C@H](N)C[C@H](N)[C@H]2O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2N)O[C@H](CO)[C@@H](O)[C@H]1O\n#Drug2: NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are complex and require a detailed analysis to understand their potential interactions.\n2. #Drug1 contains a nitrogenous base and a platinum atom, which are known to be involved in drug-drug interactions related to ototoxicity.\n3. #Drug2 has a brominated benzene ring and a carbonyl group, which may affect its metabolism and excretion.\n\nFinal answer: C. #Drug1 may increase the ototoxic activities of #Drug2.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may decrease the cardiotoxic activities of #Drug2.'], ['B', '#Drug1 may decrease the excretion rate of #Drug2 which could result in a higher serum level.'], ['C', '#Drug1 may increase the ototoxic activities of #Drug2.'], ['D', 'The serum concentration of the active metabolites of #Drug2 can be increased when #Drug2 is used in combination with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1\n#Drug2: [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C",
    "llm_output": "Analysis:\n1. The chemical structure of #Drug1 is CCCS(=O)(=O)NC1=C(F)C(C(=O)C2=CNC3=NC=C(C=C23)C2=CC=C(Cl)C=C2)=C(F)C=C1, which is a sulfonamide derivative with potential antibacterial properties.\n2. The chemical structure of #Drug2 is [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C, which is a complex molecule with multiple functional groups, potentially affecting various biological targets.\n3. The interaction between these two drugs could lead to changes in their pharmacokinetic properties, such as absorption, distribution, metabolism, or excretion.\n\nFinal answer: B. The metabolism of #Drug2 can be decreased when combined with #Drug1.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', 'The serum concentration of #Drug2 can be increased when it is combined with #Drug1.'], ['B', 'The risk or severity of QTc prolongation can be increased when #Drug1 is combined with #Drug2.'], ['C', '#Drug1 may decrease the bronchodilatory activities of #Drug2.'], ['D', '#Drug1 may increase the hepatotoxic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "B"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C\n#Drug2: [H][C@@]12CC[C@H](OC(=O)CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but without specific information about their pharmacological properties, it's challenging to determine the exact type of drug-drug interaction.\n2. The options given are related to various potential drug-drug interactions, such as changes in bioavailability, neurotoxicity, serotonergic activities, anticoagulant activities, vasoconstriction, hypertension, neuromuscular activities, nephrotoxicity, vasodilation, hyperglycemia, and hypersensitivity reactions.\n3. Without additional information about the pharmacological properties of #Drug1 and #Drug2, it's not possible to definitively determine the type of drug-drug interaction based solely on their chemical structures.\n\nFinal answer: Insufficient information to determine the type of drug-drug interaction for the given drug pair.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the hypercalcemic activities of #Drug2.'], ['B', '#Drug1 may increase the hyponatremic activities of #Drug2.'], ['C', '#Drug1 may increase the fluid retaining activities of #Drug2.'], ['D', 'The risk or severity of adverse effects can be increased when #Drug1 is combined with #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CCCC(C)C1(CC)C(=O)NC(=O)NC1=O\n#Drug2: [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1",
    "llm_output": "Analysis:\n1. The given drug pair is (#Drug1) and (#Drug2).\n2. #Drug1 is CCCC(C)C1(CC)C(=O)NC(=O)NC1=O, and #Drug2 is [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1.\n3. The possible drug-drug interactions are:\n\t* The risk or severity of hypertension can be increased when #Drug2 is combined with #Drug1.\n\t* The serum concentration of #Drug2 can be decreased when it is combined with #Drug1.\n\t* #Drug1 may decrease the vasoconstricting activities of #Drug2.\n\t* #Drug1 may decrease the cardiotoxic activities of #Drug2.\n\nFinal answer: C. #Drug1 may decrease the vasoconstricting activities of #Drug2.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', 'The risk or severity of hypertension can be increased when #Drug2 is combined with #Drug1.'], ['B', 'The serum concentration of #Drug2 can be decreased when it is combined with #Drug1.'], ['C', '#Drug1 may decrease the vasoconstricting activities of #Drug2.'], ['D', '#Drug1 may decrease the cardiotoxic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC(N)CC1=CC=C(O)C=C1\n#Drug2: COC1=CC=C(CN(CCN(C)C)C2=NC=CC=N2)C=C1",
    "llm_output": "Analysis:\n1. The given structures of #Drug1 and #Drug2 are complex, and it's difficult to predict the interaction based solely on their structures.\n2. To accurately determine the drug-drug interaction, we need to consider the pharmacological properties and known interactions of the drugs.\n3. #Drug1 has a structure similar to a benzene ring with a nitrogen atom attached, which could indicate it has sedative properties.\n4. #Drug2 has a structure with a cyanide group and a benzene ring, which could indicate it has antihypertensive properties.\n\nFinal answer: B. #Drug1 may increase the sedative activities of #Drug2.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may decrease the sedative activities of #Drug2.'], ['B', '#Drug1 may increase the hepatotoxic activities of #Drug2.'], ['C', 'The metabolism of #Drug2 can be increased when combined with #Drug1.'], ['D', 'The absorption of #Drug2 can be decreased when combined with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "B"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: \nCCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1\n#Drug2: OCC(C)(CO)C(=O)O[C@@H]1CC[C@@H](C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\\C=C(C)\\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\\C=C\\C=C\\C=C(C)\\[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)C[C@H]1OC",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific pharmacological properties are not immediately apparent from the structures alone.\n2. To determine the potential drug-drug interaction, we need to consider the known actions of each drug and how they might interact.\n3. #Drug1 has a complex structure with multiple functional groups, including an amide and an ester. This suggests it may have a variety of pharmacological effects, potentially including vasodilation, hyperglycemia, hypotension, CNS depression, and hypersensitivity reactions.\n4. #Drug2 has a more complex structure, with multiple rings and functional groups, including an ether and a carbonyl group. This suggests it may have a variety of pharmacological effects, potentially including tachycardia, protein binding, serotonergic effects, and changes in active metabolite concentrations.\n\nFinal answer: B. The protein binding of #Drug2 can be decreased when combined with #Drug1.",
    "correct_answer": "D",
    "standard_answer_range": "[['A', '#Drug1 may increase the tachycardic activities of #Drug2.'], ['B', 'The protein binding of #Drug2 can be decreased when combined with #Drug1.'], ['C', '#Drug1 may increase the serotonergic activities of #Drug2.'], ['D', 'The serum concentration of the active metabolites of #Drug2 can be increased when #Drug2 is used in combination with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "B"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1\n#Drug2: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are complex, and without specific information about their pharmacological properties, it is challenging to determine the exact type of drug-drug interaction.\n2. However, based on the given options, we can infer that the interaction might involve changes in the pharmacokinetics or pharmacodynamics of the drugs.\n3. Option A suggests an increase in vasodilatory activities, which could imply a synergistic effect on blood vessels. Option B suggests an increase in hyperglycemic activities, which could indicate a potential for increased blood sugar levels. Option C suggests an increase in hypotensive and CNS depressant activities, which could lead to a more pronounced decrease in blood pressure and CNS effects. Option D suggests an increased risk of a hypersensitivity reaction, which could be a concern for patients with allergies or sensitivity to certain drugs.\n\nFinal answer: C",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the vasodilatory activities of #Drug2.'], ['B', '#Drug1 may increase the hyperglycemic activities of #Drug2.'], ['C', '#Drug1 may increase the hypotensive and central nervous system depressant (CNS depressant) activities of #Drug2.'], ['D', 'The risk of a hypersensitivity reaction to #Drug2 is increased when it is combined with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "C"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CC1=CC(=CC=C1)N1CC(CO)OC1=O\n#Drug2: CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1",
    "llm_output": "Analysis:\n1. The given drug pair is #Drug1: CC1=CC(=CC=C1)N1CC(CO)OC1=O and #Drug2: CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1.\n2. To determine the drug-drug interaction, we need to analyze the chemical structures and properties of the drugs.\n3. #Drug1 is a compound with a benzene ring and an amide group, while #Drug2 is a compound with a benzene ring, an amide group, and a thioether group.\n4. The presence of the amide group in both drugs suggests that they may have similar pharmacological properties, such as central nervous system effects.\n5. The thioether group in #Drug2 may contribute to its neurotoxic properties.\n\nFinal answer: D. #Drug1 may increase the neurotoxic activities of #Drug2.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', 'The serum concentration of #Drug2 can be increased when it is combined with #Drug1.'], ['B', '#Drug1 may increase the central nervous system depressant (CNS depressant) and hypertensive activities of #Drug2.'], ['C', '#Drug1 may increase the hyperkalemic activities of #Drug2.'], ['D', '#Drug1 may increase the neurotoxic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "D"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: ClCCN(CCCl)P1(=O)NCCCO1\n#Drug2: CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but they do not provide any direct information about their potential interactions.\n2. We need to consider the general types of drug-drug interactions, such as increased or decreased metabolism, altered protein binding, changes in bioavailability, or increased risk of adverse effects.\n3. Without specific information about the mechanisms of action or known interactions of these drugs, we cannot definitively determine the type of interaction based solely on their chemical structures.\n\nFinal answer: Insufficient information to determine the type of drug-drug interaction for the given drug pair.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may increase the hepatotoxic activities of #Drug2.'], ['B', 'The risk or severity of adverse effects can be increased when #Drug1 is combined with #Drug2.'], ['C', '#Drug1 may increase the adverse neuromuscular activities of #Drug2.'], ['D', 'The bioavailability of #Drug2 can be increased when combined with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@@]12C[C@@H](O)[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3\n#Drug2: CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their functional groups and mechanisms of action are not explicitly stated.\n2. The question asks about the type of drug-drug interaction between #Drug1 and #Drug2, which could involve various mechanisms such as increased or decreased effectiveness, altered side effects, or increased risk of adverse reactions.\n3. Without specific information about the drugs' mechanisms of action, it is challenging to determine the exact nature of the interaction. However, we can still analyze the provided options and eliminate those that are less likely based on general pharmacological principles.\n\nFinal answer: Based on the available information, it is not possible to definitively determine the type of drug-drug interaction between #Drug1 and #Drug2. Further information about their mechanisms of action and pharmacological properties is needed to make a more accurate assessment.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the analgesic activities of #Drug2.'], ['B', '#Drug1 may increase the thrombogenic activities of #Drug2.'], ['C', '#Drug1 may increase the neuromuscular blocking activities of #Drug2.'], ['D', '#Drug1 may increase the hypotensive and central nervous system depressant (CNS depressant) activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12\n#Drug2: N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C=C2)C(I)=C1)C(O)=O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their functional groups and potential interactions are not immediately apparent.\n2. To determine the type of drug-drug interaction, we need to consider the known effects and properties of each drug, as well as any common mechanisms of action or potential side effects.\n3. #Drug1 is a long-chain alkyl nitrile, while #Drug2 is a cyclic compound with an amine group and an ester functional group. The specific interactions between these two drugs are not clear from their structures alone.\n\nFinal answer: It is not possible to definitively determine the type of drug-drug interaction between #Drug1 and #Drug2 based solely on their chemical structures. Further information about their pharmacological properties and potential interactions is needed.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may decrease the excretion rate of #Drug2 which could result in a higher serum level.'], ['B', '#Drug1 may increase the arrhythmogenic activities of #Drug2.'], ['C', '#Drug1 may decrease the diuretic activities of #Drug2.'], ['D', '#Drug1 may decrease the anticoagulant activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: [H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=C(O)C(=O)CC[C@]12C\n#Drug2: [H][C@]12C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\C=C\\[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]1C(O)=O)O2",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific functional groups and mechanisms of action are not immediately apparent.\n2. The question asks about the type of drug-drug interaction between #Drug1 and #Drug2, which could involve various mechanisms such as altered excretion, increased toxicity, or changes in bioavailability.\n3. To determine the interaction, we need to consider the potential effects of #Drug1 on #Drug2, such as increased excretion, altered metabolism, or changes in the risk or severity of adverse effects.\n\nFinal answer: B. #Drug1 may increase the excretion rate of #Drug2 which could result in a lower serum level and potentially a reduction in efficacy.",
    "correct_answer": "A",
    "standard_answer_range": "[['A', '#Drug1 may increase the hypokalemic activities of #Drug2.'], ['B', '#Drug1 may increase the excretion rate of #Drug2 which could result in a lower serum level and potentially a reduction in efficacy.'], ['C', '#Drug1 may increase the immunosuppressive activities of #Drug2.'], ['D', '#Drug1 may increase the constipating activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "B"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12\n#Drug2: CNC[C@H](O)C1=CC(O)=CC=C1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their functional groups and potential interactions are not immediately obvious.\n2. To determine the type of drug-drug interaction, we need to consider the known effects and mechanisms of action of each drug.\n3. #Drug1 has a structure similar to a fatty acid or lipid, while #Drug2 contains a phenolic group and a hydroxyl group.\n\nFinal answer: D. The risk or severity of adverse effects can be increased when #Drug1 is combined with #Drug2.",
    "correct_answer": "C",
    "standard_answer_range": "[['A', '#Drug1 may increase the thrombogenic activities of #Drug2.'], ['B', '#Drug1 may increase the analgesic activities of #Drug2.'], ['C', '#Drug1 may increase the vasopressor activities of #Drug2.'], ['D', 'The risk or severity of adverse effects can be increased when #Drug1 is combined with #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "D"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1\n#Drug2: COC1=CC(C(O)CNC(=O)CN)=C(OC)C=C1",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific pharmacological properties and potential interactions are not immediately apparent from the structures alone.\n2. To determine the type of drug-drug interaction, we need to consider the known effects and mechanisms of action of each drug, as well as any documented interactions between similar compounds.\n3. #Drug1 contains a phenyl group and an ether linkage, while #Drug2 has a carbonyl group and an amide linkage. These functional groups may influence the drugs' solubility, metabolism, and potential for interaction with other drugs.\n\nFinal answer: Without more information about the specific pharmacological properties and potential interactions of #Drug1 and #Drug2, it is not possible to definitively determine the type of drug-drug interaction for this drug pair. Further analysis and data on the drugs' mechanisms of action and documented interactions would be necessary to provide a conclusive answer.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the antiplatelet activities of #Drug2.'], ['B', '#Drug1 may increase the tachycardic activities of #Drug2.'], ['C', '#Drug1 may increase the atrioventricular blocking (AV block) activities of #Drug2.'], ['D', 'The bioavailability of #Drug2 can be increased when combined with #Drug1.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  },
  {
    "model_name": "internlm2.5-20b",
    "dataset": "Drug-Drug-Interaction",
    "key_answer_type": "alphabet_option",
    "question": "What type of drug-drug interaction is for the drug pair (#Drug1) and (#Drug2)?\n#Drug1: OC1=NC=NC2=C1C=NN2\n#Drug2: CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[C@H]1C(O)=O",
    "llm_output": "Analysis:\n1. The chemical structures of #Drug1 and #Drug2 are provided, but their specific functional groups and mechanisms of action are not detailed. This makes it difficult to determine the exact nature of their interaction.\n2. The question asks about the type of drug-drug interaction between #Drug1 and #Drug2. The possible answers are related to various potential effects, such as increased stimulatory activities, thrombogenic activities, hypersensitivity reactions, decreased antiplatelet activities, increased absorption, hypoglycemic activities, fluid retaining activities, increased photosensitizing activities, decreased analgesic activities, increased myelosuppressive activities, increased metabolism, increased ulcerogenic activities, increased vasodilatory activities, increased hyperglycemic activities, increased hypotensive and CNS depressant activities, and hypersensitivity reactions.\n3. Without more information about the specific functional groups and mechanisms of action of #Drug1 and #Drug2, it is not possible to definitively determine the type of drug-drug interaction between them.\n\nFinal answer: Insufficient information to determine the type of drug-drug interaction between #Drug1 and #Drug2.",
    "correct_answer": "B",
    "standard_answer_range": "[['A', '#Drug1 may increase the adverse neuromuscular activities of #Drug2.'], ['B', 'The risk of a hypersensitivity reaction to #Drug2 is increased when it is combined with #Drug1.'], ['C', '#Drug1 may increase the antihypertensive activities of #Drug2.'], ['D', '#Drug1 may decrease the diuretic activities of #Drug2.']]",
    "is_correct": 0,
    "extracted_answer": "[No valid answer]"
  }
]